Drug class: Empathogen–entactogen; stimulant
Other names: MDMA, Ecstasy, E, X, XTC, Molly
Onset of action: 30–45 minutes (orally)
Peak: 1.5 to 2 hours
Read our Research
Our MDMA treatment manual, Investigator’s Brochure (IB), Developmental Safety Update Report (DSUR), accounts of healing, and other important resources and information on MDMA.
Posttraumatic Stress Disorder (PTSD)
PTSD is a chronic, debilitating mental health disorder that occurs following a traumatic event.
Eating disorders are characterized by disturbances in behaviors, thoughts and attitudes to food, eating, and body weight or shape.
Anxiety disorder studies
Studies to determine the effects of MDMA on social anxiety in autistic adults and anxiety associated with life-threatening illnesses.
Unique clinical trials sponsored and implemented by clinicians to investigate a specific research question they have interest in furthering within their field
Ways to Participate
- FDA has designated MDMA-assisted therapy for PTSD a Breakthrough Therapy.
- MAPS’ Phase 3 clinical trial of MDMA-assisted therapy demonstrated statistically significant improvement in PTSD symptoms after three sessions.
- MDMA has been administered to approximately 1,700 human subjects with only one serious adverse reaction.
Did you know?
See what’s happening in today’s MDMA news.
Statement: Psychedelic-Assisted Therapies Allowed in Australia Through Special Access Scheme
February 3, 2023
FOR IMMEDIATE RELEASE: February 3, 2023 The Therapeutic Goods Administration (TGA) in Australia announced today that they will permit limited use of certain psychedelic-assisted therapies for the treatment …
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial
January 5, 2023
The world’s most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed
November 17, 2022
FOR IMMEDIATE RELEASE: November 17, 2022 MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase …
Two Expanded Access Study Sites Now Open for Enrollment
May 11, 2022
Two new study sites are now enrolling for our MDMA-assisted therapy for PTSD Expanded Access program. The Pearl Institute in Waynesville, North Carolina, and Sage Integrative Health in Berkeley, California, …
Expanded Access Study Site in California Begins Screening
March 22, 2022
Our Expanded Access Program study site at Sage Integrative Health in Berkeley, California, began screening participants for MDMA-assisted therapy for PTSD in early March. Our multi-site expanded access …
Participant Experiences & “Cover Story”
March 1, 2022
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
Ten Phone Screenings Conducted in Expanded Access Study for MDMA-Assisted Therapy for PTSD
February 5, 2022
Our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was activated for phone …
Phone Screenings Open and Site Initiation Visits Conducted at Study Sites for Expanded Access Program for MDMA-Assisted Therapy for PTSD
January 24, 2022
On December 10, 2021, our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was …
MAPS and Vine Ventures Pioneer Novel Regenerative Funding Structure to Infuse Psychedelic-Assisted Therapy Research and Access With Timely $70 Million
December 2, 2021
Revenue share payments will be based on North America sales of MDMA for use in MDMA-assisted therapy, will terminate after 8 years, and include a reciprocity payment structure that reduces payments once …
California State Senate Takes Step To Dismantle Psychedelic Prohibition
June 23, 2021
Fifty years after the War on Drugs was officially declared and psychedelic substance prohibition began in contravention of evidence supporting therapeutic use, the California State Senate has taken the …
Publication of MAPP1 Results in Nature Medicine: A Message from Amy Emerson, MAPS PBC CEO
May 11, 2021
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this …
MDMA-Assisted Therapy for PTSD in couples may reduce PTSD symptoms and improve couples’ happiness
December 8, 2020
A Phase 1/2 open-label treatment development study of MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in dyads in which one member has chronic posttraumatic stress disorder (PTSD) shows MDMA-Assisted …